# Cx611-0204 SEPCELL Study

> **NCT03158727** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tigenix S.A.U.** · enrollment: 84 (actual)

## Conditions studied

- Bacterial Pneumonia

## Interventions

- **BIOLOGICAL:** Cx611
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03158727
- **Lead sponsor:** Tigenix S.A.U.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-30
- **Primary completion:** 2020-07-07
- **Final completion:** 2020-07-07
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158727, "Cx611-0204 SEPCELL Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03158727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*